Modality
Multispecific
MOA
IL-23i
Target
AuroraA
Pathway
Cell Cycle
ALLHeart Failure
Development Pipeline
Preclinical
Oct 2017
→ Aug 2030
PreclinicalCurrent
NCT07268818
2,747 pts·Heart Failure
2017-10→2028-04·Terminated
NCT04024918
280 pts·Heart Failure
2019-01→2030-08·Completed
3,027 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-04-042.0y awayInterim· Heart Failure
2030-08-254.4y awayInterim· Heart Failure
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Termina…
Preclinical
Complet…
Catalysts
Interim
2028-04-04 · 2.0y away
Heart Failure
Interim
2030-08-25 · 4.4y away
Heart Failure
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07268818 | Preclinical | Heart Failure | Terminated | 2747 | Biomarker |
| NCT04024918 | Preclinical | Heart Failure | Completed | 280 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| SND-4562 | Syndax | NDA/BLA | AuroraA |